Use of ticagrelor alongside fibrinolytic therapy in patients with ST‐segment elevation myocardial infarction: Practical perspectives based on data from the TREAT study. Issue 10 (16th October 2018)

• Record Type: Journal Article
• Authors: Berwanger, Otavio; Abdelhamid, Magdy; Alexander, Thomas; Alzubaidi, Abdulmajeed; Averkov, Oleg; Aylward, Philip; Contreras Zúñiga, Eduardo; Halvorsen, Sigrun; Iglesias, Ricardo; A. SK. Abdul Kader, Muhamad; Zubaid, Mohammad; AlHabib, Khalid F.
• Is Part Of: Clinical cardiology. Volume 41:Issue 10(2018)
• Page Start: 1322
• Page End: 1327
• Publication Date: 2018-10-16
• Subjects: fibrinolysis -- reperfusion therapy -- ST‐segment elevation myocardial infarction -- ticagrelor -- TREAT study; Cardiology -- Periodicals; 616.12005
• DOI: 10.1002/clc.23043
• Languages: English
• ISSNs: 0160-9289

Abstract

Abstract : Primary percutaneous coronary intervention (PCI) is the preferred reperfusion method in patients with ST‐segment elevation myocardial infarction (STEMI). In patients with STEMI who cannot undergo timely primary PCI, pharmacoinvasive treatment is recommended, comprising immediate fibrinolytic therapy with subsequent coronary angiography and rescue PCI if needed. Improving clinical outcomes following fibrinolysis remains of great importance for the many patients globally for whom rapid treatment with primary PCI is not possible. For patients with acute coronary syndrome who underwent primary PCI, the PLATO trial demonstrated superior efficacy of ticagrelor relative to clopidogrel. Results in the predefined subgroup of patients with STEMI were consistent with the overall PLATO trial. Patients who received fibrinolytic therapy in the 24 hours before randomization were excluded from PLATO, and there is thus a lack of data on the safety of using ticagrelor in conjunction with fibrinolytic therapy in the first 24 hours after STEMI. The TREAT study addresses this knowledge gap; patients with STEMI who had symptom onset within the previous 24 hours and had received fibrinolytic therapy (of whom 89.4% had also received clopidogrel) were randomized to treatment with ticagrelor or clopidogrel (median time between fibrinolysis and randomization: 11.5 hours). At 30 days, ticagrelor was found to be non‐inferior to clopidogrel for the primary safety outcome of Thrombolysis in Myocardial Infarction (TIMI)‐defined first major bleeding. Considering together the results of the PLATO and TREAT studies, initiating or switching to treatment with ticagrelor within the first 24 hours after STEMI in patients receiving fibrinolysis is reasonable.